190 related articles for article (PubMed ID: 35631358)
1. Covalent Inhibition of the
Serrano-Aparicio N; Ferrer S; Świderek K
Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631358
[TBL] [Abstract][Full Text] [Related]
2. Theoretical study of the inhibition mechanism of human 20S proteasome by dihydroeponemycin.
Serrano-Aparicio N; Świderek K; Moliner V
Eur J Med Chem; 2019 Feb; 164():399-407. PubMed ID: 30611981
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic and thermodynamic characterization of oxathiazolones as potent and selective covalent immunoproteasome inhibitors.
Mihalovits LM; Ferenczy GG; Keserű GM
Comput Struct Biotechnol J; 2021; 19():4486-4496. PubMed ID: 34471494
[TBL] [Abstract][Full Text] [Related]
5. Identification of a new series of amides as non-covalent proteasome inhibitors.
Scarbaci K; Troiano V; Micale N; Ettari R; Tamborini L; Di Giovanni C; Cerchia C; Grasso S; Novellino E; Schirmeister T; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Apr; 76():1-9. PubMed ID: 24561716
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z
Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024
[TBL] [Abstract][Full Text] [Related]
7. Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes.
Grover A; Shandilya A; Bisaria VS; Sundar D
BMC Genomics; 2010 Dec; 11 Suppl 4(Suppl 4):S15. PubMed ID: 21143798
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling on porphyrin derivatives as β5 subunit inhibitor of 20S proteasome.
Arba M; Nur-Hidayat A; Ruslin ; Yusuf M; Sumarlin ; Hertadi R; Wahyudi ST; Surantaadmaja SI; Tjahjono DH
Comput Biol Chem; 2018 Jun; 74():230-238. PubMed ID: 29674291
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach.
Groll M; Huber R
Biochim Biophys Acta; 2004 Nov; 1695(1-3):33-44. PubMed ID: 15571807
[TBL] [Abstract][Full Text] [Related]
10. Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol.
Tsitsanou KE; Hayes JM; Keramioti M; Mamais M; Oikonomakos NG; Kato A; Leonidas DD; Zographos SE
Food Chem Toxicol; 2013 Nov; 61():14-27. PubMed ID: 23279842
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore-based virtual screening for identifying β5 subunit inhibitor of 20S proteasome.
Arba M; Nur-Hidayat A; Surantaadmaja SI; Tjahjono DH
Comput Biol Chem; 2018 Dec; 77():64-71. PubMed ID: 30243108
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
Li A; Sun H; Du L; Wu X; Cao J; You Q; Li Y
J Mol Model; 2014 Nov; 20(11):2515. PubMed ID: 25394401
[TBL] [Abstract][Full Text] [Related]
13. Proteasome structure, function, and lessons learned from beta-lactone inhibitors.
Groll M; Potts BC
Curr Top Med Chem; 2011 Dec; 11(23):2850-78. PubMed ID: 21824111
[TBL] [Abstract][Full Text] [Related]
14. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone.
McCormack TA; Cruikshank AA; Grenier L; Melandri FD; Nunes SL; Plamondon L; Stein RL; Dick LR
Biochemistry; 1998 May; 37(21):7792-800. PubMed ID: 9601040
[TBL] [Abstract][Full Text] [Related]
15. Quantum mechanics/molecular mechanics minimum free-energy path for accurate reaction energetics in solution and enzymes: sequential sampling and optimization on the potential of mean force surface.
Hu H; Lu Z; Parks JM; Burger SK; Yang W
J Chem Phys; 2008 Jan; 128(3):034105. PubMed ID: 18205486
[TBL] [Abstract][Full Text] [Related]
16. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
Awoonor-Williams E; Abu-Saleh AAA
Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
[TBL] [Abstract][Full Text] [Related]
17. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the Cruzain Cysteine Protease Reversible and Irreversible Covalent Inhibition Mechanism.
Silva JRA; Cianni L; Araujo D; Batista PHJ; de Vita D; Rosini F; Leitão A; Lameira J; Montanari CA
J Chem Inf Model; 2020 Mar; 60(3):1666-1677. PubMed ID: 32126170
[TBL] [Abstract][Full Text] [Related]
19. Kinetic characterization of the chymotryptic activity of the 20S proteasome.
Stein RL; Melandri F; Dick L
Biochemistry; 1996 Apr; 35(13):3899-908. PubMed ID: 8672420
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
